B16-F1小鼠黑色素瘤細(xì)胞（
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 公司名稱(chēng) 上海富雨生物科技有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/2/12 8:58:54
- 訪問(wèn)次數(shù) 47
聯(lián)系方式：陳壽彬18956075901 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息，謝謝!
小鼠黑色素瘤細(xì)胞B16-F1
| 種屬 | 小鼠 |
| 別稱(chēng) | B16/F1;B16 F1;B16F1 |
| 組織來(lái)源 | 皮膚 |
| 疾病 | 小鼠黑色素瘤 |
| 傳代比例/細(xì)胞消化 | 1:2傳代,，消化1-2分鐘 |
| 培養(yǎng)基配置 | RPMI1640培養(yǎng)基；10%胎牛血清,；1%雙抗 |
| 簡(jiǎn)介 | B16-F1細(xì)胞是B16-F0細(xì)胞的亞系,，源自黑色素瘤C57BL/6J荷瘤小鼠的皮膚；B16-F1細(xì)胞可產(chǎn)生黑色素 |
| 形態(tài) | 上皮細(xì)胞樣 |
| 生長(zhǎng)特征 | 貼壁生長(zhǎng) |
| 倍增時(shí)間 | 每周2至3次 |
| 致瘤性 | Yes,in syngeneic mice. |
| 保藏機(jī)構(gòu) | ATCC;CRL-6323 |
malignant transformation and tumor progression; (b) the ability to detect them with robust, reliable, and clinically applicable assays; and (c) their prognostic or predictive value, as validated in clinical trials.Identifying biomarkers that have predictive value for patient selection based on the likelihood of benefiting from anticancer immunotherapy is a lengthy and complex process. To date, few predictive biomarkers for anticancer immunotherapy have been robustly analytically
采購(gòu)中心
化工儀器網(wǎng)